Related Experiment Video
Updated: Jun 16, 2026
07:54
Cholesterol Efflux Assay
Published on: March 6, 2012
[Ezetimibe (Ezetrol) in patients with diabetes]
1Université de Liège.
Revue Medicale De Liege
|February 11, 2010
Summary
Ezetimibe effectively lowers cholesterol by inhibiting intestinal absorption, offering synergistic effects with statins, particularly for type 2 diabetes patients at high cardiovascular risk.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Endocrinology
Context:
- Ezetimibe selectively inhibits cholesterol and phytosterol absorption in the intestine.
- A fixed-dose combination of ezetimibe and simvastatin (Inegy) leverages synergistic cholesterol-lowering mechanisms.
- Type 2 diabetes patients face elevated cardiovascular risk, necessitating effective lipid-lowering strategies.
Purpose:
- To review recent advancements and specific considerations for using ezetimibe in patients with type 2 diabetes.
- To highlight the role of ezetimibe in managing dyslipidemia within this high-risk population.
Summary:
- Ezetimibe acts by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein, reducing cholesterol absorption.
- Its combination with statins, which inhibit hepatic cholesterol synthesis, provides additive lipid-lowering benefits.
- Clinical studies have focused on ezetimibe's efficacy and safety profile in type 2 diabetes mellitus patients.
Impact:
- Ezetimibe offers a valuable therapeutic option for improving lipid profiles in diabetic individuals.
- Understanding its specific use in this population can help mitigate cardiovascular complications.
- This review provides insights into optimizing ezetimibe therapy for enhanced patient outcomes.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...